Ryvu Therapeutics S.A. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was PLN 12.86 million compared to PLN 0.032 million a year ago. Revenue was PLN 18.32 million compared to PLN 6.79 million a year ago.

Net loss was PLN 17.6 million compared to PLN 26.54 million a year ago. Basic loss per share from continuing operations was PLN 0.79 compared to PLN 1.45 a year ago. Diluted loss per share from continuing operations was PLN 0.79 compared to PLN 1.45 a year ago.